Sanofi Infant Respiratory-Virus Drug Meets Primary Endpoint in Phase 3 Trial
April 26 2021 - 02:43AM
Dow Jones News
By Cecilia Butini
Sanofi SA said Monday that its infant respiratory-virus drug
Nirsevimab met its primary endpoint in a Phase 3 trial.
The French pharmaceutical company said the drug, which was being
investigated as a single-dose immunization against respiratory
syncytial virus, provided statistically significant reductions in
lower respiratory tract infections in infants.
The drug has been developed in partnership with AstraZeneca PLC.
Regulatory submissions are expected to begin in 2022, Sanofi
said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 26, 2021 02:28 ET (06:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024